This website is for healthcare professionals only in the U.K. Prescribing information and Adverse Event reporting can be found at the bottom of the page.
You have questions? We have answers.
NUCEIVA is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.1
Please first refer to Section 6.6 of the Nuceiva Summary of Product Characteristics. NUCEIVA should only be administered by healthcare practitioners with appropriate qualifications and expertise in the treatment of glabellar lines and the use of required equipment.
Nuceiva is manufactured in South Korea.
NUCEIVA should only be administered by healthcare practitioners with appropriate qualifications and expertise in the treatment of glabellar lines and the use of required equipment.
Hi-Pure Technology is our patented manufacturing process2.
For more information - ask your multichannel manage. For more information – contact us here.
Nuceiva lasts up to 4 months.1
Nuceiva® injections significantly reduced the severity of glabellar lines by 1 point or greater at maximum frown for up to 139 days, as measured by the investigator assessment of glabellar line severity at maximum frown.
Nuceiva acts in 2 days1
At day 2, the percentages of responders in each of the Nuceiva®, Botox® and placebo groups were 54.2%, 57.0%, and 12.2%, respectively. The test of superiority of Nuceiva® vs placebo was highly statistically significant: the absolute difference in the percentages of responders was 41.9% (P < 0.001)
Please first refer to the Nuceiva Summary of Product Characteristics for administration contraindications, precautions, warnings and instructions. NUCEIVA should only be administered by healthcare practitioners with appropriate qualifications and expertise in the treatment of glabellar lines and the use of required equipment.
Please speak to your MCM for more information.
We offer training to support the use of our product. We also hold regular online and in person events. To express interest in upcoming face to face events click here.
We have relationships with Key Opinion Leaders, in both the United States & Europe, who inject suitable patients with Nuceiva and educate other HCPs on injection technique. For more information on KOL training please contact our MCM team here.
Welcome to Aesthetics! There are many courses available for those looking to get into the industry. These are mostly offered by schools, KOL's or independent operators. We don't have a vendor that we endorse. If you have any questions about our product - please don't hesitate to get in touch with one of our MultiChannel Managers. You'll be able to book a call here.
Do you know the 5 glabellar types? The glabellar is one of the most complex facial muscular structures. In recognition of this complexity and the need for precise injection technique, we have some focused training available. Please register here.
Evolus is a performance beauty company - in the words of David Moatazedi, our CEO: we've taken lessons from the beauty industry such as reacting to trends and understanding the consumer a little better, and applied them to pharmaceutical performance standards.
We are so sorry to hear that. Please book a conversation with us here. We will do our best to help.
Thank you for wanting to give kudos! Our team work very hard, and they love the aesthetic industry. You can send as an email here and we will make sure the team member you're impressed with is rewarded.
Nuceiva is licensed in 35 countries. If you have specific questions about how you can access Nuceiva in specific countries - please speak to your MCM.
Reporting forms and information can be found at yellowcard.mhra.gov.uk/ or search MHRA yellow card in the Google Play or Apple App Store.
Adverse events should also be reported to Evolus International Ltd.
Please contact Evolus Europe Medical Information by medicalinformation@evolus.com or calling 08000541302.
Evolus clinical trial details can be found here. For any additional information, please email medicalinformation@evolus.com
Evolus is unable to provide advice on personal medical matters. Please consult your healthcare professional for specific, health-related advice and support.Links to the electronic medicines compendium (emc) website to access the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SmPC) for our medicine in the United Kingdom is also available here.
NUCEIVA PRESCRIBING INFORMATION
Legal category: POM. List price: 50 unit vial - £75.50
REPORTING OF SIDE EFFECTS FOR THE UNITED KINGDOM
Adverse events should be reported.Reporting forms and information can be found at yellowcard.mhra.gov.uk/ or search MHRA yellow card in the Google Play or Apple App Store.
Adverse events should also be reported to Evolus International Ltd.
Please contact Evolus Europe Medical Information by medicalinformation@evolus.com or calling 08000541302.
